Bradmer Pharmaceuticals (GLX) Stock Forecast & Price Target

Bradmer Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 3 Analyst Ratings

Sell
0

Hold
0

Buy
3

Consensus Price Target

N/A

Get the Latest News and Ratings for GLX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Bradmer Pharmaceuticals and its competitors.

GLX Analyst Ratings Over Time

Type	Current Forecast 10/23/23 to 10/22/24	1 Month Ago 9/23/23 to 9/22/24	3 Months Ago 7/25/23 to 7/24/24	1 Year Ago 10/23/22 to 10/23/23
Strong Buy	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	N/A
Buy	2 Buy rating(s)	2 Buy rating(s)	2 Buy rating(s)	N/A
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	N/A
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	N/A
Consensus Price Target	N/A	N/A	N/A	N/A
Forecasted Upside	N/A	N/A	N/A	N/A
Consensus Rating	Buy	Buy	Buy	N/A

Watch this before it gets removed (Ad)

If you missed it, my emergency election broadcast is now available - but will be removed soon

Click here to watch it now.

GLX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

GLX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Bradmer Pharmaceuticals Stock vs. The Competition

Type	Bradmer Pharmaceuticals	Companies
Consensus Rating Score	3.33	3.26
Consensus Rating	Buy	Buy
News Sentiment Rating	Neutral News See Recent GLX News	Neutral News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating
10/10/2024	HC Wainwright 2 of 5 stars	M. Colonnese Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/13/2024	Stifel Canada 0 of 5 stars	B. Papanastasiou Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy
12/15/2023	Atb Cap Markets 5 of 5 stars	M. Toner Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 11:17 PM ET.

GLX Forecast - Frequently Asked Questions

: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bradmer Pharmaceuticals in the last twelve months. There are currently 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GLX shares.
: According to analysts, Bradmer Pharmaceuticals's stock has a predicted downside of NaN based on their 12-month stock forecasts.
: Over the previous 90 days, Bradmer Pharmaceuticals's stock had 1 upgrade by analysts.
: Bradmer Pharmaceuticals has been rated by research analysts at HC Wainwright in the past 90 days.
: Analysts like Bradmer Pharmaceuticals more than other "" companies. The consensus rating score for Bradmer Pharmaceuticals is 3.33 while the average consensus rating score for "" companies is 3.26. Learn more on how GLX compares to other companies.

Stock Forecasts and Research Tools

Today's Ratings

Top Rated Stocks

More Ratings Tools

[625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

This page (TSE:GLX) was last updated on 10/22/2024 by MarketBeat.com Staff

From Our Partners